OBSOLETE: Infantile striatothalamic degeneration

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1575
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Infantile striatothalamic degeneration is an extremely rare neurological condition that was historically described as a distinct disorder affecting the brain, specifically the striatum and thalamus — two deep brain structures involved in movement control, sensation, and other vital functions. The term is now considered obsolete in medical classification, meaning that cases once labeled with this diagnosis have likely been reclassified under other, better-understood genetic or metabolic conditions as medical knowledge has advanced. In the original descriptions, affected infants typically showed severe neurological problems beginning very early in life, including abnormal muscle tone, movement difficulties, developmental delay, and progressive loss of brain function. The condition was associated with degeneration (breakdown) of nerve cells in the striatum and thalamus, which are critical relay centers in the brain. Because this diagnosis is now obsolete, families who were given this label in the past should work with a clinical geneticist or pediatric neurologist to determine whether modern genetic testing can identify a more specific underlying cause. Advances in genetic sequencing have allowed many previously unclassified conditions to be matched to specific gene changes, which can guide treatment and family planning decisions. Treatment has generally been supportive, focusing on managing symptoms such as seizures, feeding difficulties, and movement problems.

Key symptoms:

Severe developmental delayAbnormal muscle tone (too stiff or too floppy)Involuntary movementsDifficulty feedingSeizuresLoss of previously learned skillsPoor head controlIrritabilityFailure to thriveVision problemsDifficulty swallowing

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Infantile striatothalamic degeneration.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Infantile striatothalamic degeneration at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Infantile striatothalamic degeneration community →

No specialists are currently listed for OBSOLETE: Infantile striatothalamic degeneration.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Infantile striatothalamic degeneration.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Infantile striatothalamic degenerationForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Infantile striatothalamic degeneration.

Start the conversation →

Latest news about OBSOLETE: Infantile striatothalamic degeneration

No recent news articles for OBSOLETE: Infantile striatothalamic degeneration.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has modern genetic testing been done to identify the specific cause of my child's condition?,Would whole exome or whole genome sequencing be helpful in our case?,Are there any treatable conditions that could explain my child's symptoms?,What is the best seizure management plan for my child?,What feeding and nutrition support does my child need?,Are there any clinical trials or research studies we should consider?,What palliative or supportive care services are available to help our family?

Common questions about OBSOLETE: Infantile striatothalamic degeneration

What is OBSOLETE: Infantile striatothalamic degeneration?

Infantile striatothalamic degeneration is an extremely rare neurological condition that was historically described as a distinct disorder affecting the brain, specifically the striatum and thalamus — two deep brain structures involved in movement control, sensation, and other vital functions. The term is now considered obsolete in medical classification, meaning that cases once labeled with this diagnosis have likely been reclassified under other, better-understood genetic or metabolic conditions as medical knowledge has advanced. In the original descriptions, affected infants typically showe

At what age does OBSOLETE: Infantile striatothalamic degeneration typically begin?

Typical onset of OBSOLETE: Infantile striatothalamic degeneration is infantile. Age of onset can vary across affected individuals.